Synovitis: What the Research Says
Evidence from 25 peer-reviewed studies
What Professionals Should Know
- •Intra-articular orthobiologic therapies are a safe and evidence-supported treatment option for managing naturally occurring OA and lameness in horses, but product selection should be based on individual case assessment pending more specific clinical guidance
- •When considering orthobiologics for your clients, recognize that current evidence does not yet distinguish which specific therapy (blood vs. MSC-derived), joint location, or OA stage responds best—future case documentation with standardized outcome measures will improve practice protocols
- •Advocate for detailed case records and outcome tracking in your practice; standardized data collection across the industry will accelerate development of clearer clinical guidelines for orthobiologic application
- •While APS did not improve lameness or clinical swelling in this acute synovitis model, histological improvements suggest potential value may not be captured by lameness exams alone; consider joint pathology rather than solely clinical signs when evaluating treatment response.
- •Single APS injection may modify tissue pathology in early synovitis, but timing (24 hours post-induction) and dosing protocols require further investigation before clinical recommendations can be made.
- •Individual horse variability in both inflammatory response and APS composition means treatment response is unpredictable; this study does not support routine APS use as a standard treatment for acute synovitis based on current evidence.
- •Meloxicam effectively controls lameness from experimentally-induced synovitis and may provide clinical benefit in managing acute joint inflammation cases
- •NSAIDs like meloxicam appear to modulate systemic inflammatory markers (temperature, hemoglobin, neutrophil response) in acute synovitis
- •Joint circumference measurements alone are insufficient to assess inflammatory response; lameness scoring and systemic markers provide better clinical indicators
- •Combining sEH and COX inhibitors may offer superior pain relief and cartilage protection in joint disease compared to NSAIDs alone—consider investigating dual-therapy protocols for horses with osteoarthritis
- •sEH inhibitors appear to have disease-modifying potential by protecting cartilage cells from inflammatory damage, not just symptom relief
- •This work supports exploring sEH inhibitors as adjunctive therapy alongside traditional NSAIDs for conditions like radiocarpal joint disease
- •While stem cell injections are safe, their anti-inflammatory effects may not be effective in acute inflammatory conditions like synovitis induced by IL-1β
- •Allogeneic stem cells present a practical alternative to autologous cells given equivalent safety profiles and easier logistics for clinical use
- •Practitioners should consider that stem cell therapy effectiveness may depend on the inflammatory stage and underlying pathology, and may not be suitable as a primary treatment for acute joint inflammation
- •Intra-articular samarium-153 microspheres show promise as a synovectomy method for chronic synovitis, but the technique currently requires radioactive materials and careful handling protocols not yet routine in equine practice
- •This treatment induced temporary lameness and joint inflammation (48-72 hours post-injection), so affected horses would require stall rest during recovery; long-term clinical efficacy and safety data in naturally-occurring synovitis cases are needed before clinical adoption
- •Consider this as emerging research indicating future possibilities for treating chip-induced or inflammatory joint disease when conventional joint treatments have failed—not yet a standard clinical option
- •Early fragment removal, particularly for dorsally located fragments, may help prevent future cartilage damage in athletic horses rather than waiting for clinical signs to develop
- •Fragment size alone should not guide removal decisions; older horses and lame horses with fragments have higher risk of concurrent cartilage injury
- •Palmar/plantar located fragments may carry lower cartilage injury risk than dorsal fragments, potentially justifying more conservative management in some cases
- •Intra-articular injection of allogeneic cord blood MSCs (10 million cells) reduced lameness in carpal and fetlock synovitis, with improvements sustained through Day 42
- •Activated and non-activated MSC preparations showed similar efficacy, suggesting simpler non-activated preparations may be practical alternatives for clinical use
- •This pilot data supports further investigation of MSCs as a treatment option for synovitis-related lameness, though controlled comparison to standard treatments is needed
- •This LPS model provides a reliable experimental tool for studying transient joint inflammation and lameness in Standardbred horses, useful for evaluating new anti-inflammatory treatments
- •NSAIDs (meloxicam) effectively prevent lameness manifestation even when synovitis develops, suggesting prostaglandin-mediated pain is key to clinical expression
- •The rapid onset (4 hours) and resolution (48 hours) of lameness in this model makes it suitable for short-term intervention studies
- •Understanding inflammatory markers and lubricant changes in early synovitis may help identify biomarkers for early joint disease detection and monitoring in lame horses
- •Different joint insult mechanisms (cytokine-induced vs. mechanical lavage) produce distinct synovial fluid inflammatory profiles, suggesting different therapeutic targets may be needed
- •Serial synovial fluid analysis could potentially guide treatment decisions in managing joint inflammation and preserving articular cartilage
- •High-volume arthroscopic lavage alone is insufficient treatment for septic arthritis—expect persistent positive cultures even after 20 liters, particularly with S. aureus infections
- •Post-lavage bacterial culture should not be used as the sole indicator of treatment success; adjunctive systemic antibiotics and additional therapeutic interventions are essential
- •S. aureus infections require more aggressive treatment protocols than gram-negative organisms; expect greater bacterial persistence regardless of lavage volume
- •Cannabinoid receptors are present in equine joint synovium and become more active during inflammation, suggesting potential therapeutic targets for managing joint pain and synovitis
- •The upregulation of these receptors with synovitis indicates cannabinoid-based treatments may have a role in managing inflammatory joint conditions in horses
- •Further research is needed to determine which specific synovial cell types express these receptors and how cannabinoid therapies might be optimized for equine joint disease
- •Chronic joint inflammation in osteoarthritis appears driven by loss of macrophage homeostatic function rather than a simple M1/M2 shift; future treatments should focus on restoring resolution mechanisms rather than just suppressing inflammation.
- •Measuring synovial fluid IL-10 and MCP-1 ratios may help identify joints where inflammatory resolution has failed and guide intervention timing.
- •Current anti-inflammatory approaches may be insufficient; consider therapeutic strategies that actively promote tissue healing and inflammatory resolution once diagnosis is confirmed.
- •This technique enables tissue collection for joint research in standing horses without general anesthesia, reducing costs and recovery time compared to traditional methods
- •The tarsocrural joint model using reIL-1β provides a controlled experimental system for testing new joint therapies relevant to hock disease management
- •Practitioners can monitor lameness objectively throughout experimental protocols when using this minimally invasive approach, improving the validity of pain assessment studies
- •MSC therapies for joint disease will trigger an inflammatory response even in healthy joints; monitor for transient synovitis and lameness in the first 10 days post-injection
- •Allogeneic MSC products may behave differently from autologous cells and require separate safety evaluation protocols
- •Pre-injection and post-injection synovial fluid sampling may help distinguish MSC-induced inflammation from complications or adverse reactions
- •Synovial fluid from horses with joint injuries contains multipotent mesenchymal stem cells that can be expanded in culture for potential cell therapy applications
- •These SF-derived cells demonstrate the ability to differentiate into cartilage-producing chondrocytes, offering a promising regenerative approach for articular cartilage defects in racehorses
- •This technique provides a minimally invasive source of autologous stem cells from existing joint pathology that could support post-arthroscopic cartilage regeneration
- •Immune-mediated polysynovitis should be considered in horses presenting with multi-joint effusions, fever and systemic signs, particularly when septic arthritis has been ruled out.
- •Synovial fluid analysis and histological examination of synovial membrane are essential for diagnosis; immunoglobulin staining can confirm immune-mediated pathology.
- •Immunosuppressive therapy (dexamethasone combined with azathioprine) is an effective treatment approach, but monitor for disease recurrence if cytotoxic drugs are discontinued prematurely.
- •Radiation synovectomy with Ho-166 FHMA may offer an alternative treatment for chronic fetlock joint inflammation when conventional therapies have failed
- •The technique requires specialized nuclear medicine facilities and careful handling of radioactive materials, limiting practical availability for most equine practices
- •Further clinical efficacy and safety studies needed before widespread adoption as standard treatment for equine joint disease
- •This model demonstrates that horses tolerate repeated controlled joint inflammation with minimal welfare consequences, providing a reliable research tool for studying recurrent joint disease mechanisms.
- •The differential biomarker responses across repeated insults suggest that cartilage adaptation occurs with recurrent inflammation, which may inform understanding of how equine joints respond to repeated trauma or infection in clinical practice.
- •Recovery to baseline parameters by 8 weeks post-final injection indicates that single episodes of LPS-induced inflammation do not appear to cause lasting joint damage in this model, though clinical relevance to naturally occurring recurrent joint disease requires further validation.
- •OA requires individualized management based on its specific etiology (trauma, overuse, or degenerative), as it is not a single disease—tailor prevention and treatment accordingly.
- •Anti-inflammatory treatments targeting macrophage activity and innate immunity may offer better long-term outcomes than approaches that only address acute inflammation symptoms.
- •Understanding immune modulation in OA can help practitioners select from various therapeutic options (including novel immunotherapies) based on individual horse response and disease stage.
- •Different joints respond differently to the same inflammatory stimulus—findings from one joint cannot be automatically extrapolated to another when designing treatment or understanding clinical presentation
- •Synovitis from inflammatory insult can persist clinically and cytologically for 2+ weeks, informing expectations for recovery timelines in horses with joint inflammation
- •The distal joint (tibiotarsal) mounted a more pronounced systemic inflammatory response, suggesting potential differences in inflammatory cascade intensity between anatomical locations
- •SAA measurement in both serum and synovial fluid can help differentiate septic arthritis from aseptic synovitis, with septic cases showing significantly elevated SAA while synovitis cases remain normal
- •Serum SAA rises faster than synovial SAA in septic arthritis, making serum sampling useful for early diagnosis before synovial changes are apparent
- •Handheld SAA assays are reasonably reliable for clinical use (98% agreement at low concentrations), though numeric comparisons with lab assays should be interpreted cautiously at higher concentrations
- •Understanding the link between coagulation activation and joint inflammation may inform future therapeutic targets for managing joint disease in horses
- •Anti-inflammatory and anticoagulant strategies may have complementary roles in treating acute synovitis, though clinical validation is needed
- •The temporal expression patterns suggest early intervention after joint injury may be critical to prevent cascade amplification of inflammation
- •Low-dose doxycycline can be used therapeutically for osteoarthritis management in horses without the concern of promoting bacterial resistance at typical equine pathogenic doses
- •This approach offers a practical, affordable option for managing joint inflammation and cartilage degradation in equine practice
- •The dual benefit of MMP-13 inhibition suggests doxycycline may slow degenerative processes while maintaining normal bacterial flora
- •Ultrasound should be used alongside radiography when examining distal interphalangeal joint problems, as it reveals soft tissue changes that X-rays miss
- •Familiarity with normal ultrasonographic anatomy in both transverse and longitudinal views is essential for accurate identification of pathology
- •This imaging modality is particularly useful for detecting early synovitis and cartilage changes before they become radiographically apparent
Key Research Findings
13 studies met inclusion criteria for systematic review; 4 RCTs included in meta-analysis evaluating orthobiologic therapies for naturally occurring OA in horses
Orthobiologic therapies (blood-derived and MSC-derived) demonstrated effective long-term lameness reduction and safety profile in horses with naturally occurring osteoarthritis
Significant heterogeneity between studies prevented specific recommendations for particular orthobiologic types, affected joints, OA stages, or intended use
Current evidence base limited by lack of standardized study designs, inconsistent definitions and compositions of orthobiologic products, and absence of direct comparisons between treatment types
Single intra-articular APS injection did not reduce lameness or joint circumference compared to untreated controls in IL-1β-induced synovitis.
Synovial fluid parameters (protein, cell counts, cytokines, PGE2) showed no significant differences between APS-treated and control joints.
APS treatment significantly decreased gross pathology and synovial membrane histopathology scores, suggesting potential disease-modifying effects.
Study limitations included use of an induced model, inter-horse variability in IL-1β response, and variable APS constituent composition between individual horses.
Meloxicam treatment prevented clinically significant lameness at 2, 4, and 8 hours post-synovitis induction, while control group showed progressive lameness
Meloxicam-treated horses exhibited lower rectal temperature 4 hours after synovitis induction compared to controls
Control group demonstrated increased neutrophils with decreased total hemoglobin and hematocrit 8 hours post-induction, indicating systemic inflammatory response
No significant changes in synovial fluid composition were detected between treatment and control groups
Combined COX and sEH inhibition provided superior joint pain control compared to either drug alone in LPS-induced joint inflammation
sEH inhibition combined with phenylbutazone improved collagen synthesis-degradation balance, whereas COX inhibition alone did not
sEH inhibition alone or with COX inhibitors protected chondrocytes from TNF-α-induced apoptosis, but COX inhibition alone was ineffective
Evidence Base
Systematic review and meta-analysis of positive long-term effects after intra-articular administration of orthobiologic therapeutics in horses with naturally occurring osteoarthritis.
Mayet Anna, Zablotski Yury, Roth Susanne Pauline et al. (2023) — Frontiers in veterinary science
Single injection of intra-articular autologous protein solution in horses with acute interleukin-1B-induced synovitis decreases joint pathology scores.
Usimaki Alexandra, Ciamillo Sarah A, Barot Dhvani et al. (2025) — Equine veterinary journal
de Carvalho Júlia Ribeiro Garcia, Del Puppo Debora, Littiere Thayssa de Oliveira et al. (2024) — Frontiers in veterinary science
Targeting Soluble Epoxide Hydrolase and Cyclooxygenases Enhance Joint Pain Control, Stimulate Collagen Synthesis, and Protect Chondrocytes From Cytokine-Induced Apoptosis.
Tucker Laura, Trumble Troy N, Groschen Donna et al. (2021) — Frontiers in veterinary science
Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.
Colbath Aimée C, Dow Steven W, Hopkins Leone S et al. (2020) — Equine veterinary journal
Evaluation of samarium-153 for synovectomy in an osteochondral fragment-induced model of synovitis in horses.
Yarbrough T B, Lee M R, Hornof W J et al. (2000) — Veterinary surgery : VS
Evaluation of cartilage injury in horses with osteochondral fragments in the metacarpo-/metatarsophalangeal joint: A study on 823 arthroscopies.
Goldkuhl Janna Evelina Cornelia, Zablotski Yury, Sill Volker et al. (2024) — Equine veterinary journal
A Pilot Study to Assess the Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for the Treatment of Synovitis in Horses.
Seabaugh Kathryn, Rao Sangeeta, Koenig Judith B et al. (2024) — Animals : an open access journal from MDPI
The lipopolysaccharide model for the experimental induction of transient lameness and synovitis in Standardbred horses.
Van de Water E, Oosterlinck M, Korthagen N M et al. (2021) — Veterinary journal (London, England : 1997)
Investigation of synovial fluid lubricants and inflammatory cytokines in the horse: a comparison of recombinant equine interleukin 1 beta-induced synovitis and joint lavage models.
Watkins Amanda, Fasanello Diana, Stefanovski Darko et al. (2021) — BMC veterinary research
The effect of arthroscopic lavage volume on bacterial culture of egress fluid in horses with experimentally induced septic arthritis and synovitis.
Friedlund Alannah M, Bracamonte Jose L, Koziy Roman V et al. (2025) — Veterinary surgery : VS
Cannabinoid receptors are expressed in equine synovium and upregulated with synovitis.
Miagkoff Ludovic, Girard Christiane A, St-Jean Guillaume et al. (2023) — Equine veterinary journal
Macrophage Activation in the Synovium of Healthy and Osteoarthritic Equine Joints.
Menarim Bruno C, Gillis Kiersten H, Oliver Andrea et al. (2020) — Frontiers in veterinary science
Assessment of a novel equine tarsocrural experimental joint disease model using recombinant interleukin-1β and arthroscopic articular sampling of the medial malleolus of the tibia on the standing sedated horse.
Nelson B B, King M R, Frisbie D D (2017) — Veterinary journal (London, England : 1997)
Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.
Ardanaz N, Vázquez F J, Romero A et al. (2016) — BMC veterinary research
Multipotency of equine mesenchymal stem cells derived from synovial fluid.
Murata D, Miyakoshi D, Hatazoe T et al. (2014) — Veterinary journal (London, England : 1997)
Idiopathic immune-mediated polysynovitis in three horses.
Pusterla N, Pratt S M, Magdesian K G et al. (2006) — The Veterinary record
Radiation synovectomy with holmium-166 ferric hydroxide macroaggregate in equine metacarpophalangeal and metatarsophalangeal joints.
Mäkelä Olli, Sukura Antti, Penttilä Pirkko et al. (2003) — Veterinary surgery : VS
A Translational Model for Repeated Episodes of Joint Inflammation: Welfare, Clinical and Synovial Fluid Biomarker Assessment.
Kearney Clodagh M, Korthagen Nicoline M, Plomp Saskia G M et al. (2023) — Animals : an open access journal from MDPI
Role of Innate Immunity in Initiation and Progression of Osteoarthritis, with Emphasis on Horses.
Estrada McDermott Juan, Pezzanite Lynn, Goodrich Laurie et al. (2021) — Animals : an open access journal from MDPI
Show 5 more references
Induction of Synovitis Using Interleukin-1 Beta: Are There Differences in the Response of Middle Carpal Joint Compared to the Tibiotarsal Joint?
Colbath Aimee C, Dow Steven W, Hopkins Leone S et al. (2018) — Frontiers in veterinary science
Serum and Synovial Fluid Serum Amyloid A Response in Equine Models of Synovitis and Septic Arthritis.
Ludwig Elsa K, Brandon Wiese R, Graham Megan R et al. (2016) — Veterinary surgery : VS
mRNA expression of genes involved in inflammation and haemostasis in equine fibroblast-like synoviocytes following exposure to lipopolysaccharide, fibrinogen and thrombin.
Andreassen Stine Mandrup, Berg Lise C, Nielsen Søren Saxmose et al. (2015) — BMC veterinary research
Plasma and synovial fluid concentration of doxycycline following low-dose, low-frequency administration, and resultant inhibition of matrix metalloproteinase-13 from interleukin-stimulated equine synoviocytes.
Maher M C, Schnabel L V, Cross J A et al. (2014) — Equine veterinary journal
Ultrasonographic examination of the dorsal aspect of the distal interphalangeal joint of the horse
Dupays A.‐G., Coudry V., Denoix J.‐M. (2012) — Equine Veterinary Education